The role of tumor-infiltrating immune cells and the potential routes for successful immunotherapies in NSCLC is actively studied [15,16,17,18], which is also of interest in the ALK-rearranged subset of lung cancers because immune-based therapies showed limited efficacy in this cancer type [39]. Here, ALK is linked to lung cancer.